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Abstract Background:The optimal duration of oral steroid treatment in themanagementof acute adult asthma is un-
clear.We prospectively studied the effect of 5 vs.10 days of oral prednisolone in patients with acute asthma requiring
hospital admission.Methods: Each patient received 40mg of enteric-coated prednisolone daily for 5 days, followed by 5
days of 40mg prednisolone daily (n=24) or placebo (n=20). All were given their usual inhaled asthma therapy including
inhaled corticosteroids.Patientskept PEFand symptomdiaries for 21days.
Results:For the 5-day treatmentgroupmean (95%CI) earlymorning PEFwas 6 (47,+36) l/minlower to day 21 (P=0.78).
There was no evidence of differences in other PEF measures (morning post-bronchodilator, evening or worst of day).
One patient in each group had an exacerbation requiring further oral steroids during the 21-day observation period.
Asthma symptom scoreswereworse in the 5-daygroup on days 6221butthe significance of this findingwas uncertain,
as a difference had emerged by day 5 (prior to trial entry).Conclusions: Itmay be possible to reduce the standard steroid
course to 5 daysin acute adult asthma, provided allpatients receive inhaled steroids and a personal asthmamanagement
plan.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Systemic corticosteroids arewell established in theman-
agementof acute asthma.The optimal dose and duration
of therapy is however unknown. Di¡erent dose regimes
have been studied (1^3). A10-day course of prednisolone
with abrupt termination has been shown to be as e¡ec-
tive as a 17-day tapering course (4). BritishThoracic So-
ciety guidelines suggest 30^60mg of prednisolone for 7^
21 days (5). The potential bene¢t of corticosteroid ther-
apymustbebalanced against thepossibilityof cumulative
steroid side-e¡ects for patients who are likely to receive
several such courses during their lifetimes (6). There is
increasing concern that a patient’s risk of osteoporosis
may be related to the cumulative dose of systemic corti-Received 9 October 2001, accepted in revised form10 April 2002
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E-mail: Ronan.O’Driscoll@srht.nhs.ukcosteroid therapy (7).However, it is essential that a su⁄-
cient course be given to ensure full recovery from the
episode of acute asthma. Paediatricians, conscious of
the growth stunting e¡ect of systemic steroids, tend to
prescribe shorter courses than adult physicians.We have
compared a 5-day course of prednisolone with a 10-day
course for the treatment of adults admitted to hospital
with acute asthma.
METHODS
The study was performed at a single centre, in an 850-
bed teachinghospital in Salford,UnitedKingdom, follow-
ing the approval by the local research ethics committee.
Each patient received 40mg of enteric-coated predni-
solone daily for 5 days, followed by a further 5 days of
40mg prednisolone or placebo tablets daily. All were
treated with nebulised bronchodilators for 2 ^ 5 days.
All were discharged on inhaled beta-agonist and inhaled
steroid therapy.
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Hospital during admission for acute asthma exacerba-
tion. All eligible patients were interviewed by one of the
investigators and asked if they would bewilling to parti-
cipate in the study.Written consentwas obtained in each
case. Inclusion criteriawere acute adult asthma (peak ex-
piratory £ow {PEF}o65% predicted), admission to
hospital under the care of designated adult physicians,
age 16^60 years, ability to give informed consent and
tomaintain a PEF diary for 21days anduse of inhaled ster-
oid on discharge. The predicted PEF for each patient
was calculated using published formula for standard la-
boratory normal values (8). Exclusion criteria were: ma-
jormedical illness (such as pneumonia, heart failure, lung
cancer, and bronchiectasis), chronic pulmonary disease
other than asthma, requirement for mechanical ventila-
tion prior to randomisation, use of long-term oral corti-
costeroids, use of nebulised corticosteroids or any
recent use of oral corticosteroids prior to admission.
Demographic and medical information was recorded by
one of the investigators. Patientswere issuedwith a trial
diary and aMini-Wrightpeak £owmeter (ClementClark
International, London, U.K.) and instructed on its use.
Patients were entered in a double-blind fashion. Rando-
misation codes (5- or10-day course) were sealed in opa-
que brown envelopes and shu¥ed into random order
and then numbered sequentially. The investigator
selected the next numbered envelope for each patient
and sent it unopened to a non-blinded hospital pharma-
cist with a prescription for ‘‘steroid trial tablets’’. The
non-blinded pharmacist ensured that all patients re-
ceived the correct tablets. Patients were provided with
40mg prednisolone daily for the ¢rst 5 days, supplied as
5mg prednisolone enteric-coated tablets.For days 6^10,
each patient received 8 tablets per day of enteric-coated
prednisolone or an identical placebo tablet (supplied by
P¢zer Ltd, Sandwich,U.K.). All patients were also issued
with a supply of open-label prednisolone (40mg for
5 days) for emergencyuse and instructed that this should
be taken in the event of deteriorating asthma and
recommended to self refer to hospital under these
circumstances.
All other asthma treatment was at the discretion
of the patient’s personal physician subject to a require-
ment for all patients to receive inhaled steroid treatment
equivalent to at least 400mcg of beclomethasone
dipropionate per day. The physicians were allowed to
remove the patient from the study at their own discre-
tion. A letter was sent to the patient’s general practi-
tioner explaining the nature and purpose of the trial.
All patients were given a 4^6 week follow-up appoint-
ment in the outpatient clinic where they were reviewed
by one of the investigators and their diary cards were
collected.
Patients were asked to record their PEF on waking,
30min after their ¢rst bronchodilator treatment of theday and at bedtime before inhaled treatment.They were
also asked to record their PEF at other times if they felt
breathless (worst daily PEF). Patients recorded their
asthma symptoms daily on a numerical scorewith verbal
descriptions (modi¢ed Likert scale; 1=no symptoms, 2=
very mild, 3= mild, 4=moderate, 5=quite bad, 6=very
bad, 7=worst possible symptoms). The principal out-
comemeasures were waking PEF and asthma exacerba-
tions. Secondary outcomes were post-bronchodilator
morning PEF, evening PEF, worst PEF on each day, symp-
tom scores (overall asthma severity, wheeze severity,
cough severity, nocturnal asthma symptoms) and beta-
agonist use.
STATISTICALANALYSIS
For each individual, mean PEF and symptom scores fol-
lowing randomised allocation were calculated. These
mean scores were compared between groups using ana-
lysis of covariance in Stata version 6.0. This allowed ad-
justment for di¡erences between individuals by
controlling for the mean score for each patient prior to
day 6 treatment. Occasional missing values from diary
cards were assumed to bemissing at random.
The study was designed to recruit 75 patients in order
to have 60 patients for analysis. This was calculated to
give 80% chance (power) of detecting a15% di¡erence in
morning PEF between two groups of patients (calculated
from a previous trial of similar design) (4). The trial
stopped early due to slow recruitment, the trial was de-
signed to run in two centres but one centre was unable
to recruit due to the relocation of the proposed co-in-
vestigator.
RESULTS
Forty-seven patients entered the study of whom
44 completed the study, 20/22 in the 5-day treatment
group and 24/25 in the 10-day treatment group.
The two groups of asthmatic patients had similar
demographic features, except for a higher proportion of
patients taking a long-acting beta agonist in the 10-day
treatment group (Table 1). Two patients in the 5-day
group and1patient in the10-daygroup failed tocomplete
diaries; none of these three patients required readmis-
sion or rescue oral corticosteroid treatment and all, at
follow-up, were judged by their physician to have made
a satisfactory recovery from their acute asthma.
The groups were similar during the open-label steroid
treatment, with a mean early morning PEF of 296 and
306 l/min for the 5- and 10-day oral steroid treatment
groups, respectively. The two groups remained similar
during the randomised phase and throughout the
observation period to day 21 (Fig. 1). Each of the other
TABLE 1. Patientdemographics
10-dayoral steroid treatment
group (n=25)
5-dayoral steroid treatment
group (n=22)
Sex:
Male 7 9
Female 18 13
Age (years)* 29.8 (11.3)* 32.0 (11.0)*
Positive historyof atopy 14 12
Smokers:
Current 7 6
Ex 2 4
Predictedmean PEF (l/min)* 478 (103)* 470 (74)*
Duration of Asthma (years)* 9.6 (11.4)* 10.4 (12.0)*
Oral theophylline 3 2
Long-acting inhaled beta agonist 5 2
Meandose of inhaled steroid (beclomethasone orequivalent, mg)* 1.060 (0.544)* 0.896 (0.437)*
*values expressed asmean (SD).
FIG. 1. Morning waking PEF.Daily results in pairs:10-day treatment group ¢rst, 5-day treatment group second.Vertical boxes =
interquartile range, middle horizontal bar - = median value, vertical spikes = expected range (dots demonstrate unusually large or
smallvalues outside expectedrange).
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tween the groups (Table 2).
Mean symptom scores were similar during the initial
5-day open-label phase (Table 3). However, the
mean overall symptom scores on day 5 (when all patients
had identical therapy) were 3.2 out of seven in the 5-day
group and 2.6 out of seven in the10-day group. Although
symptoms reducedwith time in both groups, the overall
symptom score (P=0.01),wheeze (P=0.002) andnighttime
symptoms (P=0.04) were signi¢cantly higher in the 5-day
group than in the10-day group for the remainder of the
study (Table 3).There was no evidence of signi¢cant dif-
ferences in the cough scores recorded (P=0.18).There were no deaths in either group. No patients
required assisted ventilatory support. One patient
in each group had an exacerbation requiring further
oral steroids during the 21-day observation period,
during days 17^20 (10-day treatment group patient)
and days 10^15 (5-day treatment group patient).
Therewas one late exacerbation in the10-day treatment
group who required readmission to hospital (day 25)
and a further course of oral steroids. No patients in
the 5-day treatment group required readmission,
but one other patient did require a further course
of oral steroids in the late follow-up period starting
at day 36.
TABLE 2. Mean (SD) of individuals’mean PEF
Time 10-daygroup 5-daygroup Group di¡erencea
Openlabel To day 21 Openlabel To day 21 Mean (95% CI) P-value
Waking 306 (79) 398 (103) 296 (82) 383 (90) 6 (47,36) 0.78
30minb 355 (83) 435 (94) 341 (92) 415 (93) 4 (37,30) 0.83
Bedtime 357 (86) 427 (99) 348 (84) 405 (93) 16 (50,18) 0.35
Worst 273 (69) 389 (100) 277 (82) 371 (87) 20 (63,23) 0.36
aEstimated fromanalysis of covariance: negative di¡erence implies lower (worse) meanvalue in 5-daygroup.
bPEFmeasured 30min aftermorningdose of inhaled bronchodilator.
TABLE 3. Mean (SD) of individuals’ mean asthma symptom scores on a scale from 1 (no symptoms) to 7 (worst possible
symptoms)
Symptom 10-daygroup 5-daygroup Group di¡erencea
Days1^5 Days 6^21 Days1^5 Days 6^21 Mean (CI) P-value
Overall severity 3.8 (1.0) 1.9 (0.8) 3.8 (1.3) 2.6 (1.1) 0.6 (0.1,1.1) 0.01
Wheeze 4.0 (1.0) 1.9 (0.9) 3.8 (1.4) 2.6 (1.1) 0.8 (0.3,1.3) 0.002
Cough 4.1 (1.2) 2.1 (1.1) 4.0 (1.5) 2.4 (1.1) 0.4 (0.2,0.9) 0.18
Nighttime 3.6 (1.4) 1.8 (1.0) 3.7 (1.4) 2.4 (1.1) 0.6 (0.0,1.2) 0.04
Salbutamolpu¡s 22.2 (11.6) 5.8 (3.7) 20.6 (12.2) 4.8 (3.6) 0.9 (3.3,1.5) 0.45
Beclomethasone pu¡s 3.7 (1.7) 4.5 (1.7) 3.8 (1.8) 4.7 (1.5) 0.0 (0.6,0.7) 0.93
aEstimated fromanalysis of covariance: positive di¡erence implies higher (worse) meanvalue in 5-daygroup.
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This study addresses an important clinical question, the
length of steroid treatment after an asthma exacerba-
tion. A reduced duration of oral steroid treatment after
an exacerbation would be of clinical importance as it
would reduce the total steroid load and thus favourably
reduce serious steroid side-e¡ects. However, a shor-
tened course must not place patients at risk from their
asthma. The study was designed as a randomised, dou-
ble-blind, placebo-controlled trial to compare thee¡ects
of taking a 5-day course of oral prednisolone 40mg to a
10-day coursewith the same drug at the same dosage in
adults admitted to hospital because of acute asthma.The
¢nal results must be interpreted with caution, as the
number (44) of patients who completed the study was
below the intended ¢gure of 60 calculated to enable a
80% power to ¢nd a 15% di¡erence in the primary out-
comemeasure (morning PEF).
The results from the 44 patients included suggest that
there may be no clinically signi¢cant di¡erence in early
morning PEF between a 5- and 10-day course of 40mg
prednisolone for adults who are taking moderate-to-
high doses of a topically active inhaled steroid. Although
the study fell short of its intended recruitment target,con¢dence intervals for the group di¡erences in PEF at
each time of day are within715% (60 l/min) of the mean
scores. The con¢dence interval for worst PEF is consis-
tent with the possibility of clinically worse outcome
in the 5-day group. A larger multicentre trial is required
to answer this clinically important question. The
two groups of patients had similar early morning PEF at
entry into the trial and throughout days 6 ^ 21.The early
morning PEF of the 5-day treatment group continued to
rise after day 5 when oral corticosteroids were discon-
tinued, presumably due to the e¡ect of their inhaled
steroid therapy (9). There were no readmissions during
the trial, although one patient from each group required
a further course of oral corticosteroids during the
study period (days 1^21). This suggests that for the
two chief endpoints of the trial (PEF and further asthma
exacerbations), there were no important di¡erences
between the two groups with this relatively small num-
ber of patients.
The two groups had similar mean symptom scores
during the 5-day run-in treatment period during which
all patients received 40mg prednisolone daily. How-
ever, there was an unexplained but statistically insigni¢-
cant di¡erence between the two groups on day 5 (0.6
units on modi¢ed 7-point Likert scale). The di¡erence
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21 and reached statistical signi¢cance when compared
with the run-in period.The randomisation procedure re-
sulted in a disproportionate number (5 vs. 2) of patients
receiving long-acting inhaled beta-agonist treatment in
the 10-day group in comparison with the 5-day group;
however, a sub-analysis showed that this did not account
for the di¡erence in symptom scores between the two
groups.The groups were well matched for all other de-
mographic features, including age, sex, atopic status,
duration of asthma, smoking history, theophylline use
andmean predicted PEF. It is possible that the improved
symptom scores in the 10-day group may represent a
genuine di¡erence between the groups due to the addi-
tional steroid treatment in this group, or a type1error in
a secondary outcome measurement due to the small
numbers of subjects in the study. If a small di¡erence in
symptoms does truly exist, it could be debated whether
it justi¢es an additional 200mg of systemic steroid treat-
ment.
A study comparing duration of steroid treatment for
adults with acute asthma found no di¡erence in severity
of symptoms, spirometric measurements or rates of
readmission to hospital in patients receiving tapering
courses of corticosteroids over 1 or 7 weeks (10). The
use of short tapering courses has also been found to be
unnecessary in acute asthma (4). The dose of 40mg of
prednisolonewas chosen as it is commonly usedby adult
physicians (5) and is thought to be an adequate dose for
the average asthmatic patient (1).The shorter coursewill
reduce the patient’s total exposure from 400 to 200mgs
of oral prednisolone, thus decreasing the risk of steroid
side-e¡ects from cumulative courses during a lifetime
exposure. Even brief courses of systemic corticosteroids
cause reductions in trabecular bone mineral density (11)
and the cumulative e¡ects of long-termoral steroid ther-
apy have been shown to confer a substantial risk of ver-
tebral fracture in patients with chronic obstructive
pulmonary disease (6,7). However, a reduction in the
duration of the coursemustmaintain patient safety from
acute asthma, as patients admitted to hospitalwith acute
asthma are at increased risk of death from asthma (12).
The management of these patients requires more
than just a short course of oral corticosteroids. They
require intensive asthma education and a personal asth-
ma management plan (5). All should be taking an inhaled
steroid. In addition, they should be provided with a
reserve course of oral corticosteroids at home with
written instructions on when such treatment should be
taken.
It is possible that a minority of asthma patients
might bene¢t from a more prolonged course of oral
corticosteroid therapy. However, it might be best to
identify such patients individually, using agreed self-man-
agement plans based on improved PEF and symptomscores, rather than giving prolonged courses of oral cor-
ticosteroids to every patient with acute asthma. This
strategy would minimise the lifetime dose of systemic
steroids for patients with asthma whilst also minimising
the risk of undertreatment for individual high-risk
patients.
In conclusion, the optimal duration of systemic steroid
therapy for the treatment of patients with acute asthma
is an important clinical question. The current study ad-
dresses this question, but has a number of short falls, in
particular the small number of patients.The ¢ndings sup-
port the view that a 5-day course of 40mgprednisolone
may be su⁄cient for the majority of patients with acute
adult asthma provided the patient is protected by med-
ium-to-high doses of an inhaled topically active steroid
and supported by a self-management plan. A largemulti-
centre trial based on the results of this study is clearly
required to con¢dently answer this question.
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